Attitudes and Intentions toward COVID-19 Vaccination among Spanish Adults: A Descriptive Cross-Sectional Study

Diego Gabriel Mosteiro-Miguéns 1, Daniel De Bernardo Roca 2, Eva María Domínguez-Martí 1, Natalia Vieito-Pérez 3, Pilar Álvarez-Padín 4 and Silvia Novío 5,*

Citation: Mosteiro-Miguéns, D.G.; Roca, D.D.B.; Domínguez-Martí, E.M.; Vieito-Pérez, N.; Álvarez-Padín, P.; Novío, S. Attitudes and Intentions toward COVID-19 Vaccination among Spanish Adults: A Descriptive Cross-Sectional Study. Vaccines 2021, 9, 1135. https://doi.org/10.3390/vaccines9101135

Abstract: Vaccination against SARS-CoV-2 is postulated as the most effective measure to control the COVID-19 pandemic. However, the use of other protection measures is necessary to efficiently combat the spread of the virus. The aim of the present study was to determine the attitudes and intentions towards COVID-19 vaccination among non-regular social media users in Spain and to analyze how these factors could condition the acceptance of other personal protective measures once an individual has received the COVID-19 vaccine. A cross-sectional design was used in this work. In total, 719 subjects, ≥18 years old and of both sexes, were recruited from primary public healthcare centers to self-complete a questionnaire between March and April 2021. The majority of participants had a positive attitude toward vaccination and showed high levels of intention to be vaccinated. Likewise, except those participants who considered the vaccine to be the most effective measure to fight the COVID-19 pandemic, the rest of the participants highlighted the importance of continuing to limit social interactions and/or wearing masks even after being vaccinated. Since vaccination can create a perception of total immunity against SARS-CoV-2, it is necessary that healthcare staff organize effective awareness campaigns on the importance of maintaining personal protective measures until vaccination coverage is greater.

Keywords: attitude; COVID-19; intention; prevention; SARS-CoV-2; vaccines

1. Introduction

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is one of the most important health challenges of the last century [1] and is producing significant psychological, social and economic consequences [2,3]. To date, there is still no definitive treatment for this viral respiratory infection, so prevention is essential [4].

Since the beginning of the pandemic, all hopes for definitive control of the virus, especially in at-risk groups [5–8], were pinned on the development of a vaccine against SARS-CoV-2 [9]. This is because in addition to the individual protection that it offers, a vaccine’s effectiveness is based on its collective effects [10], which depend on the number of people who are willing to be vaccinated, among other factors. Since approximately 70% of the population [11,12] must be vaccinated to achieve the maximum efficacy of this biomedical strategy [11–13], one of the major concerns among health authorities, even before the approval of the vaccine by the Food and Drug Administration (FDA) or the
European Medicines Agency (EMA), has been vaccine hesitancy [14]. This concern gave rise to a considerable number of studies seeking to determine the attitudes toward COVID-19 vaccination and the intention to receive a vaccine against SARS-CoV-2 and/or the factors influencing such decisions [15,16].

There is no doubt about the usefulness of the vaccine; however, in addition to vaccination other hygiene measures, such as surface disinfection practices [17], hygienic sanitary measures such as hand hygiene [18] and the use of a hydroalcoholic solution [19], as well as physical and social distancing [20,21] and/or wearing masks [22,23], are necessary. Even though all of these measures have been useful since the beginning of the pandemic, their efficacy could be underestimated due to the appearance of vaccines, which are considered to be the most effective measure for achieving definite control of the virus [24].

Based on the aforementioned data, educational interventions provided by healthcare professionals are required, as a lack of information or misinformation could endanger control of the pandemic [25]. Thus, the objective of this study was to determine the attitudes and intentions toward COVID-19 vaccination among Spanish adults, and more specifically among non-regular social media users and analyze how these factors could condition the acceptance of other personal protective measures once an individual has received the vaccine.

2. Materials and Methods

2.1. Design

A cross-sectional, descriptive study was carried out.

2.2. Setting and Participants

The study was conducted in the Health Area of Santiago de Compostela and Barbanza, one of the 7 Galician Health Areas. A sample group of 719 subjects was recruited from primary public healthcare centers in this health area by general service, nursing and medical staff who were willing to participate in the study.

The investigation included patients of either sex, 18 years of age or older, who went to the primary public healthcare centers for any health reason. Patient companions, individuals who could not read or write in Spanish and those who had already received one dose of the COVID-19 vaccine were excluded from the study. All eligible patients within the period of the study were approached.

The size of the study population was 350,000 at the time of the research. Keeping the expected frequency of all variables at 50%, the most desirable sample size using a 95% confidence interval was determined to be 599. However, after 15% inflation and rounding, the final desired sample size was determined to be 689.

2.3. Questionnaire Design and Data Collection

The questionnaire was designed according to the advice of healthcare professionals based on a literature review [26]. A pilot study was conducted with 15 people who did not participate in the final study in order to evaluate the clarity and ease of understanding of the items, as well as the filling time, of the questionnaire. The pilot participants reported full comprehension of the questions and ease in completing the questionnaire, so only minimal changes were made following the pilot study.

The questionnaire consists of 20 items structured into four sections (Supplementary Materials Table S1). The first and second sections included 4 and 3 questions about sociodemographic characteristics (age, sex, education level and occupation) and clinical features, respectively. The third section measures participants’ attitudes towards the COVID-19 vaccine and their intentions of receiving the COVID-19 vaccination using 8 closed-ended questions and one question with a five-point Likert scale (1 = no confidence to 5 = high confidence). The last section used four questions with a five-point Likert scale (1 = strongly agree to 5 = strongly disagree) to determine the intended behaviors of the
participants related to social distancing and wearing masks in different situations after receiving the COVID-19 vaccine.

The questionnaires, which were distributed in person, were anonymous and self-completed between March and April 2021. Participants were free to omit any questions they did not want to answer. No incentive was offered for completing the questionnaire. In each primary public health care center, a person was assigned to collect and safeguard the questionnaires once they were filled in.

2.4. Ethical and Legal Considerations

The protocol of the study was evaluated by the Research Ethics Committee of Santiago-Lugo (registration code 2021/054).

After explaining the procedure and objective of the investigation, we obtained the participants’ consent and explained that their participation was completely voluntary. Pursuant to the Declaration of Helsinki and the Data Protection Act (Organic Law 3/2018), data confidentiality was guaranteed at all times.

2.5. Statistical Analysis

The results are presented as a number and percentage or mean and standard deviation. Numerical (Kolmogorov–Smirnov test; skewness; kurtosis; and the relationships between the mean, median and mode) and visual (Q–Q plot) methods were used to test the normality of the data.

Bivariate analysis was performed using ANOVA and Student’s $t$-tests for continuous variables and chi-square tests for categorical variables. Significance between multiple groups was determined using Tukey’s post hoc analysis. Throughout the study, a $p$-value less than 0.05 was considered significant. GNU PSPP 0.8.4 (Free Software Foundation Inc., Boston, MA, USA) and Epidat version 4.2 (Xunta de Galicia, Santiago de Compostela, Spain) were used for statistical processing of the data.

3. Results

3.1. Description of Sample

A total of 719 subjects chose to participate in the study. However, 33 were excluded because they were less than 18 years old ($n = 2$) or had already received one dose of the COVID-19 vaccine ($n = 31$).

Table 1 shows the sociodemographic and clinical characteristics of the participants. The sample was composed primarily of women (62%), with a mean age of 52.8 years and no relevant diseases, except for the presence of hypertension. One-third of the participants had completed secondary education, with 20% having studied at university, although almost half of the participants referred to not working at the time, they completed the questionnaire.

3.2. Attitudes toward COVID-19 Vaccine and Intention of Receiving COVID-19 Vaccination

The majority of the participants considered the vaccine to be the most effective measure for combatting the COVID-19 pandemic, especially in combination with other protective measures (item 8). Furthermore, the respondents were very willing to receive the vaccine (item 13) due to the confidence that it gave them (item 14) and its perceived level of safety (item 11). The youngest participants, those with the highest level of education, and those who had been vaccinated against the flu presented the most positive attitudes toward the vaccine and the highest intention of being vaccinated (Tables 2 and 3).
Table 1. Sociodemographic and clinical characteristics of the study’s participants (n = 686).

|                          | N (%)                        |
|--------------------------|------------------------------|
| **Age, mean (SD)**       | 52.77 (15.9)                 |
| **Sex, n (%)**           |                              |
| Male                     | 239 (34.8)                   |
| Female                   | 425 (62.0)                   |
| **Level of education, n (%)** |                          |
| Without studies          | 25 (3.6)                     |
| Primary                  | 264 (38.5)                   |
| Secondary                | 252 (36.7)                   |
| Graduate or above        | 140 (20.4)                   |
| **Occupation, n (%)**    |                              |
| Unemployed               | 134 (19.5)                   |
| Retired                  | 159 (23.2)                   |
| Livestock/Agriculture    | 32 (4.7)                     |
| Transport sector         | 20 (2.9)                     |
| Teaching                 | 30 (4.4)                     |
| Food industry            | 33 (4.8)                     |
| Catering industry        | 33 (4.8)                     |
| Other                    | 239 (34.8)                   |
| **Personal medical history, n (%)** |                        |
| Severe allergies to vaccines | 12 (1.8)                    |
| Drug allergy             | 59 (8.6)                     |
| Previous infection by SARS-CoV-2 | 24 (4.8)                  |
| COPD                     | 17 (2.5)                     |
| Asthma                   | 55 (8.0)                     |
| Hypertension             | 142 (20.7)                   |
| Myocardial infarction    | 13 (1.9)                     |
| Heart failure            | 26 (3.8)                     |
| Heart valve disease      | 34 (5.0)                     |
| Oncological disease      | 27 (3.9)                     |
| Immunosuppression        | 11 (1.6)                     |
| HIV infection / AIDS     | 2 (0.3)                      |
| Diabetes                 | 42 (6.1)                     |
| Neurological disorders   | 12 (1.8)                     |
| Pregnancy                | 22 (3.2)                     |
| Lactation                | 5 (0.7)                      |
| Other                    | 59 (8.6)                     |
| **Vaccinated against the flu in 2020, n (%)** | 283 (41.8)               |

Abbreviations: AIDS, acquired immunodeficiency syndrome; COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency virus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SD, standard deviation.
Table 2. Attitudes toward the COVID-19 vaccine, intentions of receiving COVID-19 vaccination and personal protective measures after vaccination according to age.

| Q8. Is the COVID-19 vaccine the most effective measure to fight the pandemic? | Total       | 18–39    | 40–59    | 60–79    | ≥80     | p       |
|--------------------------------------------------------------------------|-------------|----------|----------|----------|---------|---------|
| No                                                                 | 15 (2.4)    | 5 (4.6)  | 8 (2.5)  | 2 (1.5)  | 0       | 0.000   |
| Yes                                                                     | 142 (22.3)  | 17 (15.6)| 58 (18.4)| 40 (30.8)| 17 (39.5)|        |
| Yes, in combination with other protection measures                      | 480 (75.4)  | 87 (79.8)| 249 (79.1)| 88 (67.7)| 26 (60.5)|        |

| Q9. Have you looked for information on the COVID-19 vaccine in the last month? | Total       | 18–39    | 40–59    | 60–79    | ≥80     | p       |
|--------------------------------------------------------------------------|-------------|----------|----------|----------|---------|---------|
| No                                                                 | 312 (51.6)  | 54 (46.6)| 142 (48.1)| 72 (60.5)| 22 (55) | 0.084   |
| Yes                                                                     | 293 (48.4)  | 62 (53.5)| 153 (51.9)| 47 (39.5)| 18 (45) |        |

| Q11. Which of the following COVID-19 vaccines gives you the greatest security? | Total       | 18–39    | 40–59    | 60–79    | ≥80     | p       |
|--------------------------------------------------------------------------|-------------|----------|----------|----------|---------|---------|
| Pfizer–BiNtech                                                          | 202 (41.3)  | 34 (38.6)| 96 (39.2)| 46 (48.9)| 13 (39.4)| 0.255   |
| Moderna                                                                 | 21 (4.3)    | 2 (2.3)  | 11 (4.5) | 4 (4.3)  | 2 (6.1) |        |
| Both                                                                    | 234 (47.9)  | 47 (53.4)| 123 (50.2)| 37 (39.4)| 14 (42.4)|        |
| None                                                                    | 29 (5.9)    | 5 (5.7)  | 12 (4.9) | 7 (7.5)  | 4 (12.1)|        |
| Other                                                                   | 3 (0.6)     | 0        | 3 (1.2)  | 0        | 0       |        |

| Q12. According your knowledge, do you believe that you should receive the COVID-19 vaccine? | Total       | 18–39    | 40–59    | 60–79    | ≥80     | p       |
|--------------------------------------------------------------------------|-------------|----------|----------|----------|---------|---------|
| No                                                                 | 27 (4.8)    | 10 (10.9)| 12 (4.4) | 5 (4.2)  | 0       | 0.008   |
| Yes                                                                     | 531 (95.2)  | 82 (89.1)| 261 (95.6)| 114 (95.8)| 40 (100)|        |

| Q13. Would you get the COVID-19 vaccine?                                  | Total       | 18–39    | 40–59    | 60–79    | ≥80     | p       |
|--------------------------------------------------------------------------|-------------|----------|----------|----------|---------|---------|
| No                                                                 | 59 (10.2)   | 10 (9.3) | 25 (8.6) | 18 (15.5)| 4 (11.4)| 0.210   |
| Yes                                                                     | 520 (89.8)  | 98 (90.7)| 266 (91.4)| 98 (84.5)| 31 (88.6)|        |

| Q14. How much trust do you put in the vaccine?                            | Total       | 18–39    | 40–59    | 60–79    | ≥80     | p       |
|--------------------------------------------------------------------------|-------------|----------|----------|----------|---------|---------|
| Not confident at all                                                     | 21 (3.7)    | 2 (1.9)  | 13 (4.4) | 6 (5.7)  | 0       | 0.015   |
| Slightly confident                                                      | 35 (6.1)    | 11 (10.3)| 13 (4.4) | 8 (7.6)  | 1 (3.1) |        |
| Somewhat confident                                                      | 153 (26.8)  | 36 (33.6)| 73 (24.9)| 26 (24.5)| 9 (28.1)|        |
| Fairly confident                                                        | 152 (26.7)  | 33 (30.8)| 89 (30.4)| 17 (16.0)| 7 (21.9)|        |
| Completely confident                                                    | 209 (36.7)  | 25 (23.4)| 105 (35.8)| 49 (46.2)| 15 (46.9)|        |

| Q15. Do you consider the informative briefings about the COVID-19 vaccine organized by health centre staff as useful? | Total       | 18–39    | 40–59    | 60–79    | ≥80     | p       |
|--------------------------------------------------------------------------|-------------|----------|----------|----------|---------|---------|
| No                                                                      | 53 (8.9)    | 8 (7.5)  | 26 (8.9) | 14 (10.9)| 5 (13.2)| 0.165   |
| Yes                                                                     | 544 (91.1)  | 99 (92.5)| 266 (91.1)| 114 (89.1)| 33 (88.8)|        |
Table 2. Cont.

| If I was vaccinated… | Total         | Age (Years) | p   |
|----------------------|---------------|-------------|-----|
|                      |               | 18–39  | 40–59  | 60–79  | ≥80  |     |
| Q17. I would increase my social interactions in the short term |               |        |        |        |      |     |
| Strongly agree       | 55 (9.4)      | 9 (8.1)  | 26 (9)  | 15 (12.7) | 3 (9.1)  |    |
| Agree                | 141 (24.1)    | 24 (21.6) | 66 (22.8) | 33 (28.0) | 10 (30.3) | 0.143 |
| Neither agree nor disagree | 215 (36.8) | 47 (42.3) | 113 (39.1) | 35 (29.7) | 9 (27.3) |
| Disagree             | 141 (24.1)    | 28 (25.2) | 70 (24.2) | 23 (19.5) | 11 (33.3) |    |
| Strongly disagree    | 32 (5.5)      | 3 (2.7)  | 14 (4.8)  | 12 (10.2) | 0     |
| Q18. I would consider it reasonable to reduce the use of a mask with my regular contacts (friends, parents . . .) |               |        |        |        |      |     |
| Strongly agree       | 67 (11.3)     | 11 (9.6)  | 26 (9.1)  | 15 (12.7) | 7 (18.9)  |    |
| Agree                | 100 (16.9)    | 27 (23.5) | 52 (18.1) | 14 (11.9) | 1(2.7)     |
| Neither agree nor disagree | 97 (16.4) | 23 (20)  | 44 (15.3) | 18 (15.3) | 8 (21.6)  | 0.026 |
| Disagree             | 204 (34.5)    | 33 (28.7) | 113 (39.4) | 41 (34.8) | 12 (32.4) |
| Strongly disagree    | 123 (20.8)    | 21 (18.3) | 52 (18.1) | 30 (25.4) | 9 (24.3)  |
| Q19. I would consider it reasonable to reduce the use of a mask in closed public areas. |               |        |        |        |      |     |
| Strongly agree       | 60 (10.2)     | 6 (5.2)  | 34 (11.6) | 10 (8.8)  | 3 (8.6)   |    |
| Agree                | 29 (4.9)      | 6 (5.2)  | 12 (4.1)  | 5 (4.4)   | 4 (11.4)  |
| Neither agree nor disagree | 40 (6.8) | 12 (10.3) | 17 (5.8)  | 8 (7.0)   | 2 (5.7)   |
| Disagree             | 208 (35.3)    | 36 (31.0) | 113 (38.7) | 41 (36.0) | 12 (34.3) |
| Strongly disagree    | 252 (42.8)    | 56 (48.3) | 116 (39.7) | 50 (43.9) | 14 (40)   |
| Q20. I would consider it reasonable to reduce the use of a mask in open areas |               |        |        |        |      |     |
| Strongly agree       | 116 (19.5)    | 23 (19.8) | 54 (18.1) | 21 (19.1) | 7 (20.6)  |    |
| Agree                | 147 (24.8)    | 29 (25)  | 80 (26.9) | 24 (21.8) | 5 (14.7)  |
| Neither agree nor disagree | 149 (25.1) | 27 (23.3) | 80 (26.9) | 24 (21.8) | 9 (26.5)  | 0.856 |
| Disagree             | 115 (19.4)    | 25 (21.6) | 55 (18.5) | 25 (22.7) | 8 (23.5)  |
| Strongly disagree    | 67 (11.3)     | 12 (10.3) | 29 (9.7)  | 16 (14.6) | 5 (14.7)  |

Statistical significance (p < 0.05) was determined by ANOVA and Student’s t-tests. Abbreviations: Q, question. a The information about the COVID-19 vaccine was obtained from television (n = 146, 49.8%), radio (n = 48, 16.4%), print media (n = 76, 25.9%), internet (n = 214, 73.0%), healthcare professionals working in primary healthcare centers (n = 65, 22.2%), and other (n = 13, 4.4%). b The preferred healthcare professional to organize the informative briefings about the COVID-19 vaccine was: nurse (n = 43, 7.9%), doctor (n = 145, 26.7%), nurse or doctor (n = 250, 46.0%), indifferent (n = 147, 27.0%) and other (n = 2, 0.4%).
Table 3. Attitudes toward the COVID-19 vaccine, intentions of receiving COVID-19 vaccination and personal protective measures after vaccination according to sex, level of education and flu-vaccine history.

| Q8. Is the COVID-19 vaccine the most effective measure to fight the pandemic? | Sex | Level of Education | Vaccinated against the Flu in 2020 |
|---|---|---|---|
| | Male | Female | | Primary or Lower | Secondary | Graduate or Above | | No | Yes | No | Yes |
| No | 9 (4.1) | 6 (1.5) | | 8 (3.0) | 4 (1.7) | 3 (2.3) | | 14 (3.8) | 1 (0.4) | | 0.064 | 0.021 | 0.000 |
| Yes | 53 (24.2) | 82 (20.6) | | 75 (28.2) | 40 (17.0) | 25 (19.1) | | 65 (17.7) | 73 (27.8) | | 0.021 | 0.000 | 0.000 |
| Yes, in combination with other protective measures | 157 (71.7) | 310 (77.9) | | 183 (68.8) | 192 (81.4) | 103 (78.6) | | 288 (78.5) | 189 (71.9) | | 0.082 | 0.000 | 0.000 |

| Q9. Have you looked for information about the COVID-19 vaccine in the last month? | | | |
|---|---|---|---|---|
| | No | Yes | No | Yes |
| No | 123 (56.4) | 182 (49.2) | | 159 (66.8) | 117 (50.7) | 34 (25.6) | | 173 (49.2) | 136 (55.3) | | 0.054 | 0.000 | 0.082 |
| Yes | 95 (43.6) | 188 (50.8) | | 79 (33.2) | 114 (49.4) | 99 (74.4) | | 179 (50.9) | 110 (44.7) | | 0.511 | 0.000 | 0.000 |

| Q11. Which of the following COVID-19 vaccines gives you the greatest security? | Pfizer–BioNTech | Moderna | Both | None | Other |
|---|---|---|---|---|---|
| | 62 (38.8) | 134 (42.8) | | 80 (44.4) | 70 (37.8) | 51 (42.5) | | 111 (38.1) | 87 (45.3) | | 0.551 | 0.297 | 0.627 |
| | 6 (3.8) | 12 (3.8) | | 9 (5) | 9 (4.9) | 3 (2.5) | | 14 (4.8) | 7 (3.7) | | 0.000 | 0.297 | 0.627 |
| | 79 (49.4) | 152 (48.6) | | 77 (42.8) | 97 (52.4) | 60 (50) | | 146 (50.2) | 86 (44.8) | | 0.000 | 0.297 | 0.627 |
| | 11 (6.9) | 14 (4.5) | | 13 (7.2) | 9 (4.9) | 4 (3.3) | | 18 (6.2) | 11 (5.7) | | 0.000 | 0.297 | 0.627 |
| | 2 (1.3) | 1 (0.3) | | 1 (0.6) | 0 | 2 (1.7) | | 2 (0.7) | 1 (0.5) | | 0.000 | 0.297 | 0.627 |

| Q12. According your knowledge, do you believe that you should receive the COVID-19 vaccine? | | | |
|---|---|---|---|---|---|
| | No | Yes | No | Yes |
| No | 16 (8.2) | 11 (3.2) | | 7 (3.1) | 11 (5.5) | 8 (6.4) | | 25 (8.0) | 2 (0.8) | | 0.014 | 0.300 | 0.000 |
| Yes | 180 (91.8) | 333 (96.8) | | 221 (96.9) | 189 (94.5) | 118 (93.7) | | 288 (92.0) | 236 (99.2) | | 0.000 | 0.300 | 0.000 |

| Q13. Would you get the COVID-19 vaccine? | | | |
|---|---|---|---|---|
| | No | Yes | No | Yes |
| No | 24 (11.7) | 31 (8.6) | | 32 (14.8) | 18 (7.9) | 8 (6.2) | | 36 (10.8) | 22 (9.1) | | 0.241 | 0.013 | 0.506 |
| Yes | 181 (88.3) | 328 (91.4) | | 185 (85.3) | 211 (92.1) | 122 (93.9) | | 298 (89.2) | 220 (90.9) | | 0.000 | 0.013 | 0.506 |

| Q14. How much trust do you put in the vaccine? | | | |
|---|---|---|---|---|---|
| | Not confident at all | Slightly confident | Somewhat confident | Fairly confident | Completely confident |
| | 6 (3.1) | 13 (3.6) | | 11 (5.1) | 6 (2.7) | 4 (3.1) | | 15 (4.5) | 6 (2.5) | | 0.857 | 0.065 | 0.100 |
| | 13 (6.7) | 21 (5.8) | | 13 (6.1) | 13 (5.8) | 9 (7.0) | | 24 (7.2) | 11 (4.7) | | 0.085 | 0.065 | 0.100 |
| | 47 (24.2) | 100 (27.7) | | 65 (30.2) | 63 (28.1) | 24 (18.6) | | 97 (29.2) | 55 (23.3) | | 0.857 | 0.065 | 0.100 |
| | 52 (26.8) | 99 (27.4) | | 42 (19.5) | 69 (30.8) | 40 (31.0) | | 86 (25.9) | 65 (27.5) | | 0.085 | 0.065 | 0.100 |
| | 76 (39.2) | 128 (35.5) | | 84 (39.1) | 73 (32.6) | 52 (40.3) | | 110 (33.1) | 99 (42.0) | | 0.085 | 0.065 | 0.100 |
Table 3. Cont.

| Sex          | Level of Education | Vaccinated against the Flu in 2020 |
|--------------|-------------------|-----------------------------------|
| Male         | Female            | p       | Primary or Lower | Secondary | Graduate or Above | p       | No     | Yes     | p       |
| Q15. Do you consider the informative briefings about the COVID-19 vaccine organized by health centre staff as useful? |
| No           | 21 (10.1)         | 31 (8.4) | 0.482             | 23 (9.7)  | 15 (6.8)          | 13 (9.7) | 0.479   | 30 (8.8) | 23 (9.1) | 0.901   |
| Yes          | 187 (89.9)        | 340 (91.6) |                  | 215 (90.3) | 206 (93.2)          | 121 (90.3) |            | 311 (91.2) | 230 (90.9) |

If I was vaccinated . . .

Q17. I would increase my social interactions in the short term

| Sex          | Level of Education | Vaccinated against the Flu in 2020 |
|--------------|-------------------|-----------------------------------|
| Male         | Female            | p       | Primary or Lower | Secondary | Graduate or Above | p       | No     | Yes     | p       |
| Strongly agree | 29 (14.3)         | 24 (6.6) | 0.006             | 29 (12.7) | 16 (7.3)          | 10 (7.6) | 0.095   | 25 (7.2) | 30 (12.9) | 0.112   |
| Agree        | 50 (24.6)         | 86 (23.6) |                  | 65 (28.5) | 45 (20.5)          | 31 (23.5) |            | 79 (22.7) | 61 (26.2) |
| Neither agree nor disagree | 76 (37.4) | 134 (36.8) | 0.006             | 78 (34.2) | 89 (40.5)          | 47 (35.6) |            | 136 (39.1) | 77 (33.1) |
| Disagree     | 35 (17.2)         | 101 (27.8) |                  | 49 (21.5) | 54 (24.6)          | 36 (27.3) |            | 87 (25.0) | 54 (23.2) |
| Strongly disagree | 13 (6.4)         | 19 (5.2) |                  | 7 (3.1)   | 16 (7.3)           | 8 (6.1)   |            | 21 (6.0)  | 11 (4.7)  |

Q18. I would consider it reasonable to reduce the use of a mask with my regular contacts (friends, parents . . .)

| Sex          | Level of Education | Vaccinated against the Flu in 2020 |
|--------------|-------------------|-----------------------------------|
| Male         | Female            | p       | Primary or Lower | Secondary | Graduate or Above | p       | No     | Yes     | p       |
| Strongly agree | 25 (12.3)         | 40 (10.8) | 0.006             | 33 (14.7) | 24 (10.3)          | 9 (6.9)   | 0.095   | 36 (10.4) | 31 (12.8) | 0.166   |
| Agree        | 42 (20.7)         | 55 (14.9) |                  | 36 (16.1) | 37 (16.0)          | 27 (20.6) |            | 69 (20)   | 30 (12.4) |
| Neither agree nor disagree | 41 (20.2) | 56 (15.1) | 0.068             | 30 (13.4) | 45 (19.4)          | 22 (16.8) | 0.322   | 56 (16.2) | 38 (15.7) |
| Disagree     | 62 (30.5)         | 137 (37.0) |                  | 82 (36.6) | 77 (33.2)          | 45 (34.4) |            | 114 (33.0) | 90 (37.2) |
| Strongly disagree | 33 (16.3)         | 82 (22.2) |                  | 43 (19.2) | 49 (21.1)          | 28 (21.4) |            | 70 (20.3) | 53 (21.9) |

Q19. I would consider it reasonable to reduce the use of a mask in closed public areas

| Sex          | Level of Education | Vaccinated against the Flu in 2020 |
|--------------|-------------------|-----------------------------------|
| Male         | Female            | p       | Primary or Lower | Secondary | Graduate or Above | p       | No     | Yes     | p       |
| Strongly agree | 20 (10.0)         | 39 (10.5) | 0.046             | 29 (13.2) | 18 (7.8)          | 13 (9.6) | 0.000   | 33 (9.9)  | 25 (10.1) | 0.969   |
| Agree        | 17 (8.5)          | 11 (3.0) |                  | 21 (9.6)  | 3 (1.3)           | 5 (3.7)   |            | 15 (4.4)  | 13 (5.3)  |
| Neither agree nor disagree | 14 (7.0) | 26 (7.0) | 0.046             | 13 (5.9)  | 15 (6.5)          | 12 (8.9) |            | 24 (7.1)  | 16 (6.5)  |
| Disagree     | 74 (36.8)         | 129 (34.8) |                  | 84 (38.4) | 79 (34.1)          | 44 (32.6) |            | 118 (34.9) | 90 (36.4) |
| Strongly disagree | 76 (37.8)         | 166 (44.7) |                  | 72 (32.9) | 117 (50.4)         | 61 (45.2) |            | 148 (43.8) | 103 (41.7) |

Q20. I would consider it reasonable to reduce the use of a mask in open areas

| Sex          | Level of Education | Vaccinated against the Flu in 2020 |
|--------------|-------------------|-----------------------------------|
| Male         | Female            | p       | Primary or Lower | Secondary | Graduate or Above | p       | No     | Yes     | p       |
| Strongly agree | 48 (23.8)         | 65 (17.4) | 0.224             | 47 (21.3) | 39 (16.7)          | 29 (21.3) | 0.228   | 76 (21.6) | 39 (16.4) | 0.290   |
| Agree        | 51 (25.3)         | 92 (24.6) |                  | 49 (22.2) | 56 (23.9)          | 42 (30.9) |            | 92 (26.1) | 53 (22.3) |
| Neither agree nor disagree | 52 (25.7) | 92 (24.6) | 0.224             | 51 (23.1) | 67 (28.6)          | 31 (22.8) |            | 82 (23.3) | 66 (27.7) |
| Disagree     | 32 (15.8)         | 78 (20.9) |                  | 45 (20.4) | 44 (18.8)          | 26 (19.1) |            | 65 (18.5) | 50 (21.0) |
| Strongly disagree | 19 (9.4)          | 47 (12.6) |                  | 29 (13.1) | 28 (12.0)          | 8 (5.9)   |            | 37 (10.5) | 30 (12.6) |

Statistical significance (p < 0.05) was determined by a chi-square test. Abbreviations: Q, question.
More than 90% of the participants considered informative briefings about the vaccine against SARS-CoV-2 to be useful (item 15), whether such briefings were conveyed by a doctor or by a nurse. However, only half of the participants said that they had researched information about the vaccine in the last month (item 9), mainly through internet. Significant differences were not found in educational needs according to the gender, age or level of education among the participants (Tables 2 and 3).

When the participants were asked if they believed that they should receive the vaccine, more than 95% agreed (item 12). Female participants, the oldest participants and who had been vaccinated against the flu in the last year were significantly more aware of the need to have the vaccine (Tables 2 and 3). On the contrary, significant differences were not found in belief that the vaccine is necessary based on whether the participant did or did not belong to an at-risk population ($p = 0.251$).

### 3.3. Personal Protective Measures after Vaccination

The majority of the participants would not increase their social interactions even after being vaccinated (item 17), neither would they reduce the use of a mask with their regular contacts (items 18) or in closed public areas (item 19); they would consider using a mask less often only in open areas (item 20) (Table 2). However, it should be noted that when determining how the attitudes toward vaccination and/or the intention of receiving a COVID-19 vaccination could influence the use of personal protective measures after vaccination, the following significant differences were observed: i) the respondents who considered the vaccine to be the most effective measure to fight the COVID-19 pandemic noted that they would increase their social interactions in the short term and would use a mask less often, in comparison with those who did not consider the vaccine to be the most useful measure or thought that a vaccine would be a useful measure in combination with other preventive measures; ii) the respondents willing to receive the vaccine were found to be more reluctant to reduce the use of a mask in closed public places than those who were not willing to receive a vaccine (Table 4).

In general, male participants, the youngest participants and those with the lowest level of education were the most strongly in favor of reducing preventive measures against SARS-CoV-2 after being vaccinated (Tables 2 and 3).
| Q17. I would increase my social interactions in the short term | Q8. Is the COVID-19 Vaccine the Most Effective Measure to Fight the Pandemic? | Q13. Would You Get the COVID-19 Vaccine? |
|-------------------------------------------------------------|---------------------------------------------------------------|-----------------------------------------------|
| If I Was Vaccinated . . .                                   | No or Only in Combination with Other Protective Measures | No | Yes |
| Strongly agree                                              | 26 (6.1)                                                     | 7 (14.3)                                     | 38 (8.1)                                    |
| Agree                                                       | 94 (21.9)                                                    | 12 (24.5)                                    | 115 (24.4)                                  |
| Neither agree nor disagree                                  | 167 (38.9)                                                   | 18 (36.7)                                    | 171 (36.3)                                  |
| Disagree                                                    | 118 (27.5)                                                   | 8 (16.3)                                     | 121 (25.7)                                  |
| Strongly disagree                                           | 24 (5.6)                                                     | 4 (8.2)                                      | 26 (5.5)                                    |
| Statistical significance ($p < 0.05$) was determined by a chi-square test. Abbreviations: Q, question. | |

| Q18. I would consider it reasonable to reduce the use of a mask with my regular contacts (friends, parents . . .) | |
| Strongly agree                                              | 42 (9.5)                                                     | 9 (17.7)                                     | 46 (9.8)                                    |
| Agree                                                       | 71 (16.0)                                                    | 6 (11.8)                                     | 82 (17.4)                                   |
| Neither agree nor disagree                                  | 78 (17.6)                                                   | 7 (13.7)                                     | 78 (16.5)                                   |
| Disagree                                                    | 159 (35.8)                                                   | 15 (29.4)                                    | 167 (35.4)                                  |
| Strongly disagree                                           | 94 (21.2)                                                   | 14 (27.5)                                    | 99 (21.0)                                   |

| Q19. I would consider it reasonable to reduce the use of a mask in closed public areas | |
| Strongly agree                                              | 36 (8)                                                       | 9 (18.8)                                     | 39 (8.2)                                    |
| Agree                                                       | 18 (4)                                                       | 6 (12.5)                                     | 19 (4)                                      |
| Neither agree nor disagree                                  | 30 (6.7)                                                    | 4 (8.3)                                      | 31 (6.5)                                    |
| Disagree                                                    | 165 (36.7)                                                   | 14 (29.2)                                    | 171 (36)                                    |
| Strongly disagree                                           | 201 (44.7)                                                   | 15 (31.3)                                    | 215 (45.3)                                  |

| Q20. I would consider it reasonable to reduce the use of a mask in open areas | |
| Strongly agree                                              | 73 (16.1)                                                   | 12 (26.1)                                    | 87 (18.1)                                   |
| Agree                                                       | 113 (24.9)                                                   | 7 (15.2)                                     | 120 (24.9)                                  |
| Neither agree nor disagree                                  | 125 (27.6)                                                   | 12 (26.1)                                    | 129 (26.8)                                  |
| Disagree                                                    | 92 (20.3)                                                    | 8 (17.4)                                     | 94 (19.5)                                   |
| Strongly disagree                                           | 50 (11.0)                                                   | 7 (15.2)                                     | 54 (10.8)                                   |
4. Discussion

The results of the present study reveal that the attitudes and intentions of the non-regular social media users in Spain toward vaccination are favorable. However, this confidence is high enough that it could compromise the maintenance of other individual protective measures, especially among those who consider the vaccine to be the most effective measure to fight the pandemic. To our knowledge, this is the first study on determining the intention of Spanish adults to be vaccinated that obtained information using in-person questionnaires, which allowed us to reach a population group for which we had no information, as members of this group are not regular users of social media.

Even before the current pandemic, both the emergence of virulent pathogens and vaccine hesitancy were identified by the World Health Organization as potential threats to global health [27]. Different studies have evaluated the intentions of the general population toward COVID-19 vaccination, indicating considerable differences between countries. The highest intention of vaccination during the first year of the pandemic was observed in China (91.3%) [28], while the countries with the worst statistics on vaccination intention were Nigeria (29%) [29] and Kuwait (23.6%) [30]. Spain [31], France, Italy [32,33], the United Kingdom [34,35] and several other countries [36–41] instead occupy intermediate positions. In Spain, current data on vaccination intention show variable results, with percentages that range from approximately 75% [31,37] to 48.3% [42]. As it is estimated that vaccination coverage should be approximately around 70% to achieve maximum effectiveness [11–13], the Spanish estimates could suggest the inability of our country to reach the desired herd immunity threshold.

During the pandemic in Spain, fake news on COVID-19 has been published on social media and instant messaging apps [43,44], the main media outlets used by the participants of the present study to remain informed about vaccination (item 10). However, this issue does not seem to have had a negative impact on the intention to be vaccinated in our country.

Apart from the study carried out by Rodríguez-Blanco et al. [42], the rest of the studies performed using a representative sample of the general population at a national level [37], as well as samples of the population originating from different Autonomous Communities in Spain (Catalonia [31]) and Galicia [current study], show that the intention to be vaccinated has remained consistently high, as the vaccine has given the population significant confidence. This finding contrasts sharply with the results observed in other countries such as Italy, the UK and China [30,45,46], where in addition to a decrease in the intention to be vaccinated, there is evidence of an increase in a refusal to be vaccinated.

Among the different reasons referred to by the population in not accepting the vaccine, the main concerns include a fear of long-lasting health problems or side effects [38,47–50], antivaccine beliefs [38,47,51–53] and the need for more information [38,53], among others [38,47,49,54,55]. Among these reasons, a lack of vaccine safety was noted to be the main reason to refuse the vaccine [38,41,47,56–58], which could be due to the population’s lack of trust in the speed at which the vaccines were developed [59,60], as well as contradictory information given by politicians over time [42]. As stated by more than 90% of the sample in the current study (item 15), this matter highlights the need for healthcare professionals to organize informative briefings about the vaccine against SARS-CoV-2 to highlight that the vaccine is not only effective but also safe. In Spain, doctor–nurse collaboration is essential to carry out behavioral and biomedical interventions in Primary Health Care, such as vaccination campaigns, in which these healthcare professionals can not only contribute to raising awareness about the importance of becoming vaccinated but also aid in advising, diagnosing and/or monitoring potential side effects [61]. Moreover, according to the results of our study, such briefings should be mainly aimed at people with low levels of education, as such individuals showed the lowest intention to be vaccinated, as already mentioned by other authors [38,62,63].

We have yet to fully control the pandemic, as the appearance of new highly transmissible SARS-CoV-2 variants has contributed to the occurrence of new outbreaks; such
outbreaks highlight the fact that this is a very contagious virus [64–67]. Even though the vaccines are of great help in protecting people against SARS-CoV-2, these vaccines may not be effective against all the variants. Therefore, we should not mistakenly believe that the vaccine alone will control the pandemic [68,69]. Even when a person is vaccinated, new variants circulating in the community can cause COVID-19. This matter highlights the need to inform the population about the importance of using public health measures that are highly effective, such as wearing masks and engaging in social distancing, even when an individual is already vaccinated [70,71]. Indeed, in the present study, those who considered the vaccine to be the most effective measure to fight the COVID-19 pandemic also said they would increase their social interactions in the short term and would use a mask less often in the presence of their regular contacts, as well as in closed public and open areas. The effectiveness of personal protective measures has been a controversial subject over the course of the pandemic. Even though the Spanish political health authorities initially advised against wearing a mask [72], as reported by traditional communication media [73], subsequent recommendations were very different in various countries [74–78], which may have led to doubts regarding the true usefulness of such measures [79].

In Spain, an insufficient number of vaccines made it necessary to establish a vaccination strategy against COVID-19 that prioritized at-risk groups, in addition to meeting other ethical principles [8]. Thus, after health and social health workers were vaccinated, the following groups were prioritized: elderly people aged >80 followed by patients with hypertension, diabetes mellitus, cardiovascular diseases, chronic obstructive pulmonary disease, stroke, stage 3–5 chronic renal failure, hepatic cirrhosis, neoplasia and immunosuppression [3–8]. Even though these population groups (especially those above the age of 80) had the highest rates of hospitalization and mortality [80–82], in the current study, significant differences were not found between at-risk groups and other groups regarding belief in whether the vaccine is necessary.

In contrast with other studies carried out among Spanish adults to determine the intention to be vaccinated, this is the only study to date that obtained the information in person, which allowed us to acquire information on populations who are not regular users of social media. However, these results must be interpreted with caution due to some limitations. First, as the participants filled in the questionnaires themselves, there may have been some self-reporting bias. Second, we asked the participants about their intent to be vaccinated at a time when vaccination was already available. Thus, it is possible that the answers from some of the participants may have been influenced by the opinions of other people who had already been vaccinated. Third, according to the method used to obtain the information for the current study, the sample consists of non-regular social media users, which is not necessarily representative either of them or of the general population.

5. Conclusions

Since vaccination can create a perception of total immunity against SARS-CoV-2, partly due to a lack of hope in fighting the different stages of COVID-19 in the absence of effective strategies to combat the disease [83], it is necessary that healthcare professionals organize effective awareness campaigns aimed at Spanish adults, especially to non-regular social media users, on the importance of maintaining personal protective measures until vaccination is more widespread.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/vaccines9101135/s1, Table S1: Questionnaire “Actitudes e intenciones hacia la primovacunación del SARS-CoV-2 en la población general”.

Author Contributions: Conceptualization, D.G.M.-M., N.V.-P. and S.N.; data curation, D.G.M.-M., D.D.B.R., E.M.D.-M., N.V.-P. and P.A.-P.; formal analysis, D.G.M.-M. and S.N.; investigation, D.G.M.-M., D.D.B.R., E.M.D.-M. and S.N.; methodology, D.G.M.-M., D.D.B.R., E.M.D.-M., N.V.-P., P.A.-P. and S.N.; project administration, D.G.M.-M. and S.N.; supervision, D.G.M.-M. and S.N.; validation, D.G.M.-M., D.D.B.R., E.M.D.-M., N.V.-P., P.A.-P. and S.N.; visualization, D.G.M.-M., N.V.-P., P.A.-P. and S.N.; writing—original draft, D.G.M.-M., D.D.B.R. and S.N.; writing—review and editing, D.G.M.-M.,
E.M.D.-M., N.V-P., P.A.-P. and S.N. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** The protocol of the study was evaluated by the Research Ethics Committee of Santiago-Lugo (registration code 2021/054).

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** The data presented in this study are available from the corresponding author (S.N.) upon reasonable request.

**Acknowledgments:** We thank all the workers at the primary public healthcare centers of A Bandeira, A Estrada, Concepción Arenal, Oca, Padrión and Silleda for their selfless collaboration, especially those in charge of safeguarding the questionnaires during data collection, without whom this study would not have been possible: Maite Matalobos Luís, Carmen Bermúdez Virgos, Juan José Augusto Sánchez Castro, Beatriz Requeijo Villaverde, Victoria Eugenia Martínez Maestro, Berta Novegil Castro, Guadalupe Suarez Costa, Ana María Mouta Otero and José Suarez Allen.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Mallah, S.I.; Ghorab, O.K.; Al-Salmi, S.; Abdellatif, O.S.; Tharmaratnam, T.; Iskandar, M.A.; Sefen, J.A.N.; Sidhu, P.; Atallah, B.; El-Lababidi, R.; et al. COVID-19: Breaking down a global health crisis. *Ann. Clin. Microbiol. Antimicrob.* 2021, *20*, 35. [CrossRef]

2. Luo, M.; Guo, L.; Yu, M.; Jiang, W.; Wang, H. The psychological and mental impact of coronavirus disease 2019 (COVID-19) on medical staff and general public—A systematic review and meta-analysis. *Psychiatry Res.* 2020, *291*, 113190. [CrossRef]

3. Nicola, M.; Alsafi, Z.; Sohrabi, C.; Kerwan, A.; Al-Jabir, A.; Iosifidis, C.; Agha, M.; Agha, R. The socio-economic implications of the coronavirus pandemic (COVID-19): A review. *Int. J. Surg.* 2020, *78*, 185–193. [CrossRef]

4. Majumder, J.; Minko, T. Recent developments on therapeutic and diagnostic approaches for COVID-19. *AAPS J.* 2021, *23*, 14. [CrossRef] [PubMed]

5. Yang, J.; Zheng, Y.; Gou, X.; Pu, K.; Chen, Z.; Guo, Q.; Ji, R.; Wang, H.; Wang, Y.; Zhou, Y. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: A systematic review and meta-analysis. *Int. J. Infect. Dis.* 2020, *94*, 91–95. [CrossRef] [PubMed]

6. Sociedad Española de Medicina de Familia y Comunitaria. Abordaje del Paciente con Covid-19 en Atención Primaria. Available online: https://www.sesmefyc.es/wp-content/uploads/2021/02/Covid19-abordaje-01-02-2021.pdf (accessed on 25 August 2021).

7. Centers for Disease Control and Prevention. People with Certain Medical Conditions. Available online: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html (accessed on 23 August 2021).

8. Grupo de Trabajo Técnico de Vacunación COVID-19, de la Ponencia de Programa y Registro de Vacunaciones. Estrategia de Vacunación Frente a COVID-19 en España. Available online: https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/covid19/docs/COVID-19_Actualizacion8_EstrategiaVacunacion.pdf (accessed on 25 August 2021).

9. Gavriatopoulou, M.; Ntanasis-Stathopoulos, I.; Korompoki, E.; Fotiou, D.; Migkou, M.; Tzanninis, I.; Psaltopoulou, T.; Kastritis, E.; Terpos, E.; Dimopoulos, M.A. Emerging treatment strategies for COVID-19 infection. *Clin. Exp. Med.* 2021, *21*, 167–179. [CrossRef] [PubMed]

10. Gildea, F. Tackling sheepishness about a COVID-19 vaccine for the sake of herd immunity. *Perspect. Public Health* 2020, *140*, 301–302. [CrossRef] [PubMed]

11. Kwok, K.O.; Lai, F.; Wei, W.I.; Wong, S.Y.S.; Tang, J.W.T. Herd immunity—Estimating the level required to halt the COVID-19 epidemics in affected countries. *J. Infect.* 2020, *80*, e32–e33. [CrossRef]

12. Randolph, H.E.; Barreiro, L.B. Herd Immunity: Understanding COVID-19. *Immunology* 2020, *52*, 737–741. [CrossRef] [PubMed]

13. European Centre for Disease Prevention and Control. Overview of COVID-19 Vaccination Strategies and Vaccine Deployment Plans in the EU/EEA and the UK. Available online: https://www.ecdc.europa.eu/sites/default/files/documents/Overview-of-EU_EEA-UK-vaccination-deployment-plans.pdf (accessed on 12 August 2021).

14. Harrison, E.A.; Wu, J.W. Vaccine confidence in the time of COVID-19. *Eur. J. Epidemiol.* 2020, *35*, 325–330. [CrossRef]

15. Wake, A.D. The willingness to receive COVID-19 Vaccine and its associated factors: “vaccination refusal could prolong the war of this pandemic”—A systematic review. *Risk Manag. Health Policy* 2021, *14*, 2609–2623. [CrossRef]

16. Al-Jayyousi, G.F.; Sherbesh, M.A.M.; Ali, L.A.M.; El-Heneidy, A.; Alhussaini, N.W.Z.; Elhassan, M.E.A.; Nazzal, M.A. Factors influencing public attitudes towards COVID-19 vaccination: A scoping review informed by the socio-ecological model. *Vaccines* 2021, *9*, 548. [CrossRef]

17. Noorimotlagh, Z.; Mirzaee, S.A.; Jaafarzadeh, N.; Maleki, M.; Kalvandi, G.; Karami, C. A systematic review of emerging human coronavirus (SARS-CoV-2) outbreak: Focus on disinfection methods, environmental survival, and control and prevention strategies. *Environ. Sci. Pollut. Res. Int.* 2021, *28*, 1–15. [CrossRef]
18. World Health Organization & United Nations Children’s Fund (UNICEF). Water, Sanitation, Hygiene and Waste Management for the COVID-19 Virus: Interim Guidance. Available online: https://apps.who.int/iris/handle/10665/331499 (accessed on 23 August 2021).

19. Berardi, A.; Perinelli, D.R.; Merchant, H.A.; Bisharat, L.; Basheti, I.A.; Bonacucina, G.; Cespi, M.; Palmieri, G.F. Hand sanitisers amid Covid-19: A critical review of alcohol-based products on the market and formulation approaches to respond to increasing demand. *Int. J. Pharm.* 2020, 584, 119431. [CrossRef]

20. Prem, K.; Liu, Y.; Russell, T.W.; Kucharski, A.J.; Eggo, R.M.; Davies, N.; Centre for the Mathematical Modelling of Infectious Diseases COVID-19 Working Group; Jit, M.; Klepac, P. The effect of control strategies to reduce social mixing on outcomes of the COVID-19 epidemic in Wuhan, China: A modelling study. *Lancet Public Health* 2020, 5, e261–e270. [CrossRef]

21. Nussbaumer-Streit, B.; Mayr, V.; Dobreascu, A.I.; Chapman, A.; Persad, E.; Klerings, I.; Wagner, G.; Siebert, U.; Christof, C.; Zachariah, C. Quarantine alone or in combination with other public health measures to control COVID-19: A rapid review. *Cochrane Database Syst. Rev.* 2020, 4, CD013574. [CrossRef] [PubMed]

22. Li, Y.; Liang, M.; Gao, L.; Ayyaz Ahmed, M.; Uy, J.P.; Cheng, C.; Zhou, Q.; Sun, C. Face masks to prevent transmission of COVID-19: A systematic review and meta-analysis. *Am. J. Infect. Control.* 2021, 49, 900–906. [CrossRef] [PubMed]

23. Howard, J.; Jiang, J.; Wu, Z.; Tufekci, Z.; Zdimal, V.; van der Westhuizen, H.; von Delft, A.; Price, A.; Friedman, L.; Tang, L.H. An evidence review of face masks against COVID-19. *Proc. Natl. Acad. Sci. USA* 2021, 118, e2014561118. [CrossRef] [PubMed]

24. Spanish Agency for Medicines and Health Products. Estrategia de Vacunación COVID-19 en España. Available online: https://www.aemps.gob.es/la-aemps/ultima-informacion-de-la-aemps-acerca-del-covid%E2%80%919/vacunas-contra-la-covid%E2%80%919/ (accessed on 13 August 2021).

25. Roozenbeek, J.; Schneider, C.R.; Dryhurst, S.; Kerr, J.; Freeman, A.L.J.; Recchia, G.; van der Bles, A.M.; van der Linden, S. Susceptibility to misinformation about COVID-19 around the world. *R. Soc. Open Sci.* 2020, 7, 201199. [CrossRef] [PubMed]

26. Lin, Y.; Hu, Z.; Zhao, Q.; Aliass, H.; Danaee, M.; Wong, L.P. Understanding COVID-19 vaccine demand and hesitancy: A nationwide online survey in China. *PLoS Negl. Trop. Dis.* 2020, 14, e0008961. [CrossRef]

27. World Health Organization. Ten Threats to Global Health in 2019. Available online: https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019 (accessed on 23 August 2021).

28. Wang, J.; Jing, R.; Lai, X.; Zhang, H.; Lyu, Y.; Knoll, M.D.; Fang, H. Acceptance of COVID-19 vaccination during the COVID-19 pandemic in China. *Vaccines* 2020, 9, 482. [CrossRef]

29. Reuben, R.C.; Danladi, M.M.A.; Saleh, D.A.; Ejembi, P.E. Knowledge, attitudes and practices towards COVID-19: An epidemiological survey in north-central Nigeria. *J. Community Health* 2021, 46, 457–470. [CrossRef]

30. Sallam, M. COVID-19 vaccine hesitancy worldwide: A concise systematic review of vaccine acceptance rates. *Vaccines* 2021, 9, 160. [CrossRef]

31. Egúa, H.; Vinciarelli, F.; Bosque-Prous, M.; Kristensen, T.; Saig-Rubió, F. Spain’s Hesitation at the gates of a COVID-19 vaccine. *Vaccines* 2021, 9, 170. [CrossRef]

32. Detoc, M.; Bruel, S.; Frappet, P.; Tardy, B.; Botelho-Nevers, E.; Gagneux-Brunon, A. Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic. *Vaccine* 2020, 38, 7002–7006. [CrossRef]

33. Prati, G. Intention to receive a vaccine against SARS-CoV-2 in Italy and its association with trust, worry and beliefs about the origin of the virus. *Health Educ. Res.* 2020, 35, 505–511. [CrossRef] [PubMed]

34. Sherman, S.M.; Smith, L.E.; Sim, J.; Amlot, R.; Cutts, M.; Dasch, H.; Rubin, G.J.; Sevdalis, N. COVID-19 vaccination intention in the UK: Results from the COVID-19 vaccination acceptability study (CoVacS), a nationally representative cross-sectional survey. *Hum. Vaccin. Immunother.* 2021, 17, 1612–1621. [CrossRef] [PubMed]

35. Freeman, D.; Loe, B.S.; Chadwick, A.; Vaccari, C.; Waite, F.; Rosebrock, L.; Jenner, L.; Petit, A.; Lewandowsky, S.; Vandersloot, S.; et al. COVID-19 vaccine hesitancy in the UK: The Oxford coronavirus explanations, attitudes, and narratives survey (Oceans) II. *Psychol. Med.* 2020, 1–15. [CrossRef]

36. Kourlaba, G.; Kourkouni, E.; Maistrelli, S.; Tsepela, C.; Molocha, N.; Triantafyllou, C.; Konioroud, M.; Kopsidas, I.; Chorianopoulou, E.; Maroudi-Manta, S.; et al. Willingness of Greek general population to get a COVID-19 vaccine. *PLoS Negl. Trop. Dis.* 2020, 14, e0003324. [CrossRef] [PubMed]

37. Lazurus, J.V.; Ratzan, S.C.; Palayew, A.; Gostin, L.O.; Larson, H.J.; Rabin, K.; Kimball, S.; El-Mohandes, A. Author Correction: A global survey of potential acceptance of a COVID-19 vaccine. *Nat. Med.* 2021, 27, 354. [CrossRef]

38. Fisher, K.A.; Bloomstone, S.J.; Walder, J.; Crawford, S.; Fouayzi, H.; Mazor, K.M. Attitudes toward a potential SARS-CoV-2 vaccine: A survey of U.S. adults. *Intern. Med.* 2020, 173, 964–973. [CrossRef] [PubMed]

39. Largent, E.A.; Persad, G.; Sangenito, S.; Glickman, A.; Boyle, C.; Emanuel, E.J. US public attitudes toward COVID-19 vaccine mandates. *JAMA Netw. Open* 2020, 3, e2033324. [CrossRef] [PubMed]

40. Latkin, C.A.; Dayton, L.; Yi, G.; Colon, B.; Kong, X. Mask usage, social distancing, racial, and gender correlates of COVID-19 vaccine intentions among adults in the US. *PloS ONE* 2021, 16, e0246970. [CrossRef]

41. Wong, L.P.; Alias, H.; Wong, P.; Lee, H.Y.; AbuBakar, S. The use of the health belief model to assess predictors of intent to receive the COVID-19 vaccine and willingness to pay. *Hum. Vaccin. Immunother.* 2020, 16, 2204–2214. [CrossRef]

42. Rodriguez-Blanco, N.; Montero-Navarro, S.; Botella-Rico, J.M.; Felipe-Gómez, A.J.; Sánchez-Más, J.; Tuell, J. Willingness to Be Vaccinated against COVID-19 in Spain before the Start of Vaccination: A Cross-Sectional Study. *Int. J. Environ. Res. Public Health* 2021, 18, 5272. [CrossRef]
43. Herrera-Peco, I.; Jiménez-Gómez, B.; Romero Magdalena, C.S.; Deudero, J.J.; García-Puente, M.; Benítez De Gracia, E.; Ruiz Núñez, C. Antivaccine movement and COVID-19 negationism: A content analysis of spanish-written messages on twitter. *Vaccines* 2021, 9, 656. [CrossRef]

44. Singh, L.; Bansal, S.; Bode, L.; Budak, C.; Chi, G.; Kawintiranon, K.; Padden, C.; Vanarsdall, R.; Vraga, E.; Wang, Y. A first look at COVID-19 information and misinformation sharing on Twitter. *arXiv* 2020, arXiv:2003.13907.

45. Robinson, E.; Jones, A.; Lesser, I.; Daly, M. International estimates of intended uptake and refusal of COVID-19 vaccines: A rapid systematic review and meta-analysis of large nationally representative samples. *Vaccine* 2021, 39, 2024–2034. [CrossRef]

46. Wang, J.; Lu, X.; Lai, X.; Lyu, Y.; Zhang, H.; Fenghuang, Y.; Jing, R.; Li, L.; Yu, W.; Fang, H. The changing acceptance of COVID-19 vaccination in different epidemic phases in China: A longitudinal study. *Vaccines* 2021, 9, 191. [CrossRef] [PubMed]

47. Cordina, M.; Lauri, M.A.; Lauri, J. Attitudes towards COVID-19 vaccination, vaccine hesitancy and intention to take the vaccine. *Pharm. Pract.* 2021, 19, 2317. [CrossRef]

48. Neumann-Böhme, S.; Varghese, N.E.; Sabat, I.; Barros, P.B.; Brouwer, W.; van Exel, J.; Schreyögg, J.; Stargardt, T. One we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19. *Eur. J. Health Econ. 2020, 21, 977–982. [CrossRef] [PubMed]

49. Dror, A.A.; Eisenbach, N.; Taiber, S.; Morozov, N.G.; Mizrachi, M.; Zigron, A.; Srouji, S.; Sela, E. Vaccine hesitancy: The next challenge in the fight against COVID-19. *Eur. J. Epidemiol. 2020, 35, 775–779. [CrossRef] [PubMed]

50. Yin, F.; Wu, Z.; Xia, X.; Ji, M.; Wang, Y.; Hu, Z. Unfolding the determinants of COVID-19 vaccine acceptance in China. *J. Med. Internet Res. 2021, 23, e26089. [CrossRef] [PubMed]

51. Insanguine Mingarro, F.A.; Castellanos Claramunt, J. COVID-19, fake news and vaccination: The need to immunize society from vaccine hesitancy. *Cuad. Bioet.* 2021, 32, 63–73. [CrossRef] [PubMed]

52. Zarocostas, J. How to fight an infodemic. *Lancet* 2020, 395, 676. [CrossRef]

53. Pullan, S.; Dey, M. Vaccine hesitancy and anti-vaccination in the time of COVID-19: A google trends analysis. *Vaccine* 2021, 39, 1877–1881. [CrossRef]

54. Guidry, J.P.D.; Laestadius, L.I.; Vraga, E.K.; Miller, C.A.; Perrin, P.B.; Burton, C.W.; Ryan, M.; Fuemmeler, B.F.; Carlyle, K.E. Willingness to get the COVID-19 vaccine with and without emergency use authorization. *Am. J. Infect. Control. 2021, 49, 137–142. [CrossRef] [PubMed]

55. Kreps, S.; Prasad, S.; Brownstein, J.S.; Hswen, Y.; Garibaldi, B.T.; Zhang, B.; Kriner, D.L. Factors associated with US adults’ likelihood of accepting COVID-19 vaccination. *JAMA Netw. Open. 2020, 3, e2025594. [CrossRef]

56. Pogue, K.; Jensen, J.L.; Stancil, C.K.; Ferguson, D.G.; Hughes, S.J.; Mello, E.J.; Burgess, R.; Berges, B.K.; Quaye, A.; Poole, B.D. Influences on attitudes regarding potential COVID-19 vaccination in the United States. *Vaccines 2020, 8, 582. [CrossRef]

57. Ebenersteiner, F.; Ritschl, V.; Nawaz, F.A.; Fazel, S.S.; Kulnik, S.T.; Crutzen, R.; Klager, E.; Völkl-Kernstock, S.; Schaden, E.; et al. People’s willingness to vaccinate against COVID-19 despite their safety concerns: Twitter poll analysis. *J. Med. Internet Res. 2021, 23, e28973. [CrossRef]

58. Hou, Z.; Tong, Y.; Du, F.; Lu, L.; Zhao, S.; Yu, K.; Piatek, S.J.; Larson, H.J.; Lin, L. Assessing COVID-19 vaccine hesitancy, confidence, and public engagement: A global social listening study. *J. Med. Internet Res. 2021, 23, e27632. [CrossRef]

59. Nature. What the Lightning-Fast Quest for Covid Vaccines Means for other Diseases. Available online: https://media.nature.com/original/magazine-assets/d41586-020-03626-1/d41586-020-03626-1.pdf (accessed on 15 July 2021).

60. García-Montero, C.; Fraile-Martínez, O.; Bravo, C.; Torres-Carranza, D.; Sanchez-Trujillo, L.; Gómez-Lahoz, A.M.; Guijarro, L.G.; García-Honduvilla, N.; Asínso, A.; Bujan, J. An updated review of SARS-CoV-2 vaccines and the importance of effective vaccination programs in pandemic times. *Vaccines* 2021, 9, 433. [CrossRef]

61. Katzman, J.G.; Katzman, J.W. Primary care clinicians as COVID-19 vaccine ambassadors. *J. Prim. Care Community Health* 2021, 12, 21501327211007026. [CrossRef]

62. Chen, T.; Dai, M.; Xia, S.; Zhou, Y. Do messages matter? Investigating the combined effects of framing, outcome uncertainty, and number format on COVID-19 vaccination attitudes and intention. *Health Commun. 2021, 27, 1–8. [CrossRef]

63. Mesesle, M. Awareness and attitude towards COVID-19 vaccination and associated factors in Ethiopia: Cross-sectional study. *Infect. Drug Resist.* 2021, 14, 2193–2199. [CrossRef]

64. Kirby, T. New variant of SARS-CoV-2 in UK causes surge of COVID-19. *Lancet Respir. Med.* 2021, 9, e20–e21. [CrossRef]

65. van Oosterhout, C.; Hall, N.; Ly, H.; Tyler, K.M. COVID-19 evolution during the pandemic—Implications of new SARS-CoV-2 variants on disease control and public health policies. *Virulence* 2021, 12, 507–508. [CrossRef]

66. Di Carlo, P.; Falasca, K.; Ucciferri, C.; Sinjari, B.; Aruffo, E.; Antonucci, I.; Di Serafino, A.; Pompilio, A.; Damiani, V.; Mandatorì, D.; et al. Normal breathing releases SARS-CoV-2 into the air. *J. Med. Microbiol. 2021, 70, 001328. [CrossRef] [PubMed]

67. Di Carlo, P.; Chiachiarietta, P.; Sinjari, B.; Aruffo, E.; Stuppia, L.; De Laurenzi, V.; Di Tomo, P.; Pelusi, L.; Potenza, F.; Veronese, A.; et al. Air and surface measurements of SARS-CoV-2 inside a bus during normal operation. *PLoS ONE 2020, 15, e0235943. [CrossRef] [PubMed]

68. Priesemann, V.; Balling, R.; Brinkmann, M.M.; Ciesek, S.; Czyzopinka, T. An action plan for pan-European defence against new SARS-CoV-2 variants. *Lancet* 2021, 397, 469–470. [CrossRef]

69. Petersen, E.; Gökengin, A.D.; Al Balushi, A.; Zumla, A. One and a half years into the COVID-19 pandemic—Exit strategies and efficacy of SARS-CoV-2 vaccines for holistic management and achieving global control. *Turk. J. Med. Sci.* 2021, 51, Online ahead of print. [CrossRef]
70. Sahin Tutak, A.; Söylemez, F.; Konuk, H.B.; Çakmak, E.; Karakaya, B.; Doğan, A.; Sayiner, H.S.; Aksöz, S.; Alev, M. A patient presenting with ARDS after COVID-19 vaccination: A COVID-19 case report. *J. Infect. Public Health* 2021, online ahead of print. [CrossRef] [PubMed]

71. Porto, M.H.; Castro, B.; Diaz, Z.; Pedroso, Y.; Ramos, M.J.; Lecuona, M. SARS-CoV-2 infection in properly vaccinated healthcare workers. *Int. J. Infect. Dis.* 2021, online ahead of print. [CrossRef] [PubMed]

72. Claessens, M. *The Science and Politics of COVID-19. How Scientists Should Tackle Global Crises*; Springer: Cham, Switzerland, 2021.

73. Catalán-Matamoros, D.; Elias, C. Vaccine Hesitancy in the Age of Coronavirus and Fake News: Analysis of Journalistic Sources in the Spanish Quality Press. *Int. J. Environ. Res. Public Health* 2020, 17, 8136. [CrossRef] [PubMed]

74. Hsiang, S.; Allen, D.; Annan-Phan, S.; Bell, K.; Bolliger, I.; Chong, T.; Druckenmiller, H.; Huang, L.Y.; Hultgren, A.; Krasovich, E.; et al. Publisher Correction: The effect of large-scale anti-contagion policies on the COVID-19 pandemic. *Nature* 2020, 585, E7. [CrossRef] [PubMed]

75. Moloney, K.; Moloney, S. Australian quarantine policy: From centralization to coordination with mid-pandemic COVID-19 shifts. *Public Adm. Rev.* 2020. online ahead of print. [CrossRef] [PubMed]

76. Malta, M.; Strathdee, S.A.; Garcia, P.J. The brazilian tragedy: Where patients living at the ‘Earth’s lungs’ die of asphyxia, and the fallacy of herd immunity is killing people. *EClinicalMedicine* 2021, 32, 100757. [CrossRef]

77. Kaplan, S.; Lefler, J.; Zilberman, D. The political economy of COVID-19. *Appl. Econ. Perspect. Policy* 2021. online ahead of print. [CrossRef]

78. Webb, E.; Hernández-Quevedo, C.; Williams, G.; Scarpetti, G.; Reed, S.; Panteli, D. Providing health services effectively during the first wave of COVID-19: A cross-country comparison on planning services, managing cases, and maintaining essential services. *Health Policy* 2021. online ahead of print. [CrossRef]

79. Maykrantz, S.A.; Gong, T.; Petrolino, A.V.; Nobiling, B.D.; Houghton, J.D. How Trust in information sources influences preventative measures compliance during the COVID-19 pandemic. *Int. J. Environ. Res. Public Health* 2021, 18, 5867. [CrossRef]

80. Covino, M.; De Matteis, G.; Polla, D.A.D.; Santoro, M.; Burzo, M.L.; Torelli, E.; Simeoni, B.; Russo, A.; Sandroni, C.; Gasbarrini, A.; et al. Predictors of in-hospital mortality and death risk stratification among COVID-19 patients aged ≥80 years old. *Arch. Gerontol. Geriatr.* 2021, 95, 104383. [CrossRef] [PubMed]

81. Moreno-Torres, V.; de la Fuente, S.; Mills, P.; Muñoz, A.; Muñez, E.; Ramos, A.; Fernández-Cruz, A.; Arias, A.; Pintos, I.; Vargas, J.A.; et al. Major determinants of death in patients hospitalized with COVID-19 during the first epidemic wave in Madrid, Spain. *Medicine* 2021, 100, e25634. [CrossRef] [PubMed]

82. Ioannidis, J.P.A.; Axfors, C.; Contopoulou-Ioannidis, D.G. Population-level COVID-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters. *Environ. Res.* 2020, 188, 109890. [CrossRef]

83. Ucciferri, C.; Barone, M.; Vecchiet, J.; Falasca, K. Pidotimod in Paucisymptomatic SARS-CoV2 Infected Patients. *Mediterr. J. Hematol. Infect. Dis.* 2020, 12, e2020048. [CrossRef]